Literature DB >> 32988715

Clinical Significance of the Initial and Best Responses after Chemoembolization in the Treatment of Intermediate-Stage Hepatocellular Carcinoma with Preserved Liver Function.

Chan Park1, Hee Ho Chu1, Jin Hyoung Kim2, So Yeon Kim1, Ibrahim Alrashidi1, Dong Il Gwon1, Hyun-Ki Yoon1, Nayoung Kim3.   

Abstract

PURPOSE: To evaluate the clinical implications of initial and best responses during repeated transarterial chemoembolization procedures for hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: This study included 726 patients who received a diagnosis of intermediate-stage HCC with Child-Pugh class A liver function between 2007 and 2016, and who were treated with transarterial chemoembolization as the first-line treatment. Evaluation of treatment response was based on the modified response evaluation criteria in solid tumors. Overall survival (OS) was compared between response categories after implementation of landmark analysis.
RESULTS: Of the 726 patients, an objective response (complete response [CR] or partial response [PR]) was observed as the initial response in 78.1% of patients. Regarding the best response during the transarterial chemoembolization series, 87.2% of patients were overall responders. The median OS of initial responders (n = 483) was not significantly different from that of subsequent responders at the 1-year landmark (stable disease [SD] after first transarterial chemoembolization but CR or PR after repeated transarterial chemoembolization; n = 61; 46.2 vs 40.1 months, respectively; P = .145). Likewise, the median OS of initial CR patients (n = 326) was not significantly different from that of the subsequent CR group (n = 126) at the 1-year landmark (PR or SD after first transarterial chemoembolization but CR after repeated transarterial chemoembolization; 53.4 vs 46.3 months, respectively; P = .455). Multivariate Cox analyses showed that the objective responses, the initial responses (hazard ratio [HR], 0.638; P = .001), and the best responses (HR, 0.304; P < .001) had the significant prognostic significance for OS.
CONCLUSIONS: Both the initial and best responses during repeated transarterial chemoembolization were significantly associated with OS in patients with intermediate-stage HCC and preserved liver function.
Copyright © 2020 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32988715     DOI: 10.1016/j.jvir.2020.04.017

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  6 in total

1.  Combination Therapy With Lenvatinib and Radiofrequency Ablation for Patients With Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh Class A Liver function: A Pilot Study.

Authors:  Feiqian Wang; Kazushi Numata; Satoshi Komiyama; Haruo Miwa; Kazuya Sugimori; Katsuaki Ogushi; Satoshi Moriya; Akito Nozaki; Makoto Chuma; Litao Ruan; Shin Maeda
Journal:  Front Oncol       Date:  2022-05-04       Impact factor: 5.738

2.  Chemoembolization Plus Microwave Ablation vs Chemoembolization Alone in Unresectable Hepatocellular Carcinoma Beyond the Milan Criteria: A Propensity Scoring Matching Study.

Authors:  Hui-Zhou Li; Jie Tan; Tian Tang; Tian-Zhi An; Jun-Xiang Li; Yu-Dong Xiao
Journal:  J Hepatocell Carcinoma       Date:  2021-11-01

3.  Predicting the Initial Treatment Response to Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma by the Integration of Radiomics and Deep Learning.

Authors:  Jie Peng; Jinhua Huang; Guijia Huang; Jing Zhang
Journal:  Front Oncol       Date:  2021-10-21       Impact factor: 6.244

4.  Hypoalbuminemia Is a Hepatocellular Carcinoma Independent Risk Factor for Tumor Progression in Low-Risk Bridge to Transplant Candidates.

Authors:  Kelley G Núñez; Tyler Sandow; Jai Patel; Mina Hibino; Daniel Fort; Ari J Cohen; Paul Thevenot
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

5.  Bronchial artery embolization for hemoptysis caused by metastatic hepatocellular carcinoma.

Authors:  Sungwon Kim; Jin Hyoung Kim; Gi-Young Ko; Dong Il Gwon; Ji Hoon Shin; Hyun-Ki Yoon
Journal:  Sci Rep       Date:  2022-04-28       Impact factor: 4.996

Review 6.  Transarterial chemoembolization failure/refractoriness: A scientific concept or pseudo-proposition.

Authors:  Shen Zhang; Bin-Yan Zhong; Lei Zhang; Wan-Sheng Wang; Cai-Fang Ni
Journal:  World J Gastrointest Surg       Date:  2022-06-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.